Compare NGNE & TRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | TRTX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.9M | 659.4M |
| IPO Year | 2014 | N/A |
| Metric | NGNE | TRTX |
|---|---|---|
| Price | $34.41 | $8.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $63.57 | $9.83 |
| AVG Volume (30 Days) | 310.4K | ★ 687.8K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.55% |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.78 |
| Revenue Next Year | N/A | $4.14 |
| P/E Ratio | ★ N/A | $14.82 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $7.57 |
| 52 Week High | $43.66 | $9.85 |
| Indicator | NGNE | TRTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 55.74 |
| Support Level | $18.24 | $8.59 |
| Resistance Level | $37.27 | $8.73 |
| Average True Range (ATR) | 3.04 | 0.16 |
| MACD | -0.65 | 0.01 |
| Stochastic Oscillator | 17.67 | 67.00 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.